We all know, if it is the early detection of breast cancer, usually before surgery, and then the next step according to pathology for chemotherapy and radiotherapy, endocrine and, more recently the introduction of biological targeted therapy. After this treatment the vast majority of patients can be disease-free survival over 5 years. So for those who have no systemic spread locally advanced breast cancer patients with advanced, in the past can only chemotherapy or endocrine therapy, not surgery. This treatment is valid even if the short term, the remaining local lesions are always still left in the mammary gland, and will soon appear until the death of recurrence and metastasis.
Since the end of the century preoperative chemotherapy that is medically referred to neoadjuvant chemotherapy for locally advanced breast cancer patients with advanced inoperable in terms of is a big step forward. Its appearance can be markedly improved the rate of tumor resection and improve the patient’s survival.
The benefits include
1 discovered that a tumor before the operation began after systemic chemotherapy (can play on the control of micro-metastasis);
2 the use of the blood supply system has not yet destroyed, so that anti-cancer drugs to reach around the tumor in sufficient quantities to play a role;
3 in vivo drug sensitivity test;
4 is expected to drop a view to reduce the tumor size to be able to surgery;
5 for some patients who wish to retain the breast also provides an opportunity to retain the breast;
6 to avoid the use of drugs after an invalid.
These advantages make this kind may be terminally ill and had surgery.
